Dedicated High-Performance Breast PET/CT

专用高性能乳房 PET/CT

基本信息

批准号：
8103361
负责人：
RAMSEY D. BADAWI
金额：
$ 2.1万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-05-15 至 2014-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8103361
关键词：
3-Dimensional Address Anatomy Area Arts Axilla Behavior Benchmarking Biological Models Biopsy Blood Vessels Breast Breast Cancer Treatment Cancer Patient Characteristics Chest wall structure Clinic Clinical Communities Computer software Data Detection Devices Disease Drops Electronics Ensure Health Histology Human Hybrids Image Imaging Device Label Life Low Dose Radiation Magnetic Resonance Imaging Malignant Neoplasms Mammary Gland Parenchyma Mammography Mastectomy Measurement Measures Metabolic Methodology Methods Modeling Molecular Newly Diagnosed Noise Nuclear Operating System Operative Surgical Procedures Output PET/CT scan Patient Care Patients Performance Pharmaceutical Preparations Phase Play Population Positioning Attribute Positron-Emission Tomography Predictive Value Problem Solving Process Radioisotopes Reading Reporting Research Infrastructure Research Personnel Resolution Role Scheme Source Staging Staining method Stains System Techniques Technology Testing Therapeutic Three-Dimensional Image Time Tissues Tracer Translating Translations Tube Validation Woman Work analog attenuation base clinical efficacy cost data acquisition design detector drug development follow-up image reconstruction imaging modality improved in vivo malignant breast neoplasm molecular imaging mortality novel performance tests photomultiplier prototype public health relevance reconstruction response scale up simulation therapy development tool

项目摘要

DESCRIPTION (provided by applicant): Objectives: To build a high-performance, high-resolution quantitative PET/CT scanner dedicated to imaging the breast. This will permit validation of anato-metabolic imaging of the breast in the contexts of local staging, prediction of therapeutic response, follow-up for patients receiving conservative therapy and the development of new drugs for breast cancer treatment. Methods: Using a novel high-resolution, low-dead-time scintillation detector design using a dual-ended read-out scheme using APDs and PSPMTs, and a modified version of commercial PET electronics, we will build a PET scanner compact enough to fit inside the gantry of our existing breast CT scanner. We will combine the two devices to allow sequential imaging of the breast in the same clinical setting, resulting in accurately registered high-resolution functional and anatomic images. The device will be compatible with biopsy tools and will be expandable to facilitate imaging of the chest wall and axillae. Construction will be phased. At each stage we will use a continuous test/re-test approach using pre-calculated bench-marks to permit efficient and timely resolution of arising issues. We will employ state-of-the-art image reconstruction techniques using measured system models to maximize spatial resolution, and we will carefully implement all necessary data corrections for quantitative imaging. We will compare performance with whole-body PET/CT and MRI in a trial of 30 patients with known breast cancer. Health relatedness: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care. PUBLIC HEALTH RELEVANCE: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care.

描述（由申请人提供）：目标：构建专用于乳腺成像的高性能、高分辨率定量 PET/CT 扫描仪。这将允许在局部分期、预测治疗反应、对接受保守治疗的患者进行随访以及开发乳腺癌治疗新药的背景下验证乳房的解剖代谢成像。方法：采用新颖的高分辨率、低死区时间闪烁探测器设计，采用 APD 和 PSPMT 的双端读出方案，以及商用 PET 电子设备的修改版本，我们将构建一个足够紧凑的 PET 扫描仪，以适应在我们现有的乳腺 CT 扫描仪的机架内。我们将结合这两种设备，以便在相同的临床环境中对乳房进行连续成像，从而获得准确配准的高分辨率功能和解剖图像。该设备将与活检工具兼容，并且可扩展以方便对胸壁和腋窝进行成像。建设将分阶段进行。在每个阶段，我们将使用预先计算的基准进行连续测试/重新测试方法，以便有效、及时地解决出现的问题。我们将采用最先进的图像重建技术，使用测量的系统模型来最大化空间分辨率，并且我们将仔细实施定量成像的所有必要的数据校正。我们将在 30 名已知乳腺癌患者的试验中比较全身 PET/CT 和 MRI 的表现。健康相关性：迄今为止在临床上测试的乳房 PET 成像仪是低成本、低性能的设备，无法充分评估体内方法，并且不提供与 3D 解剖信息融合的 3D 图像（这项技术已在身体）。因此，大部分患有原发性乳腺癌的女性无法获得分子成像在分期和再分期、治疗研究反应和药物开发方面的已知能力。所提出的设备将解决这个问题，并允许确定足够临床表现的最低成像要求——这是将该技术转化为患者护理的先决条件。公共健康相关性：迄今为止在诊所测试的乳房 PET 成像仪是低成本、低性能的设备，无法充分评估体内方法，并且不提供与 3D 解剖信息融合的 3D 图像（一种经过充分验证的技术）体内）。因此，大部分患有原发性乳腺癌的女性无法获得分子成像在分期和再分期、治疗研究反应和药物开发方面的已知能力。所提出的设备将解决这个问题，并允许确定足够临床表现的最低成像要求——这是将该技术转化为患者护理的先决条件。